http://dx.doi.org/10.31703/gpsr.2024(IX-II).03
10.31703/gpsr.2024(IX-II).03
Published : Jun 2024
Nanocarrier-Based Therapeutics and Theranostics Drug Delivery Systems for Next Generation of Liver Cancer Nanodrug Modalities
This review focuses on the physicochemical properties of nanocarriers (NCs) and the physical properties of the tumor microenvironment (TME), highlighting strategies used to specifically deliver molecules of interest to specific lesions. This review discusses these products, explains the simple selection of high-performance and active methods, and illustrates this with examples of drugs that are focused on clinical research or treatment. The last few years have seen an increase in targeted delivery of anticancer drugs. Although many trials have been completed, only a few targets of nanocarriers have been approved for clinical use, and no interaction with nanoparticles has been confirmed. Here we review the details of these two processes and their effects on the tumor microenvironment. We also focus on the limitations and advantages of each system at both laboratory and commercial scales. The current article discusses how NC and enhanced access and retention affect passive targeting.
-
NP (nanoparticles), EPR (Enhanced permeation and retention), TME (tumor microenvironment), MDR (multiple drug resistance), HCC (hepatic cell carcinoma), SDDS (Smart Drug Delivery Systems)
-
(1) Dua Zahid
Graduate at Saulat Institute of Pharmaceuticals Sciences, QAU, Islamabad, Pakistan.
(2) Rabia Tahir
Graduate at Saulat Institute of Pharmaceuticals Sciences, QAU, Islamabad, Pakistan.
(3) Wajiha Ashfaq
Graduate at Saulat Institute of Pharmaceuticals Sciences, QAU, Islamabad, Pakistan.
(4) Abdul Wasay
Graduate at Saulat Institute of Pharmaceuticals Sciences, QAU, Islamabad, Pakistan.
(5) Qamer Iqbal
Graduate at Saulat Institute of Pharmaceuticals Sciences, QAU, Islamabad, Pakistan.
-
Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK, Marks JD, Weiner LM. 2001) High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules.
- Bae, Y. H. (2009). Drug targeting and tumor heterogeneity. Journal of Controlled Release, 133(1), 2–3. https://doi.org/10.1016/j.jconrel.2008.09.074
- Gosk, S., Moos, T., Gottstein, C., & Bendas, G. (2008). VCAM-1 directed immunoliposomes selectively target tumor vasculature in vivo. Biochimica Et Biophysica Acta (BBA) - Biomembranes, 1778(4), 854–863. https://doi.org/10.1016/j.bbamem.2007.12.021
- Gullotti, E., & Yeo, Y. (2009). Extracellularly Activated nanocarriers: a new paradigm of tumor targeted drug delivery. Molecular Pharmaceutics, 6(4), 1041–1051. https://doi.org/10.1021/mp900090z
- Haley, B., & Frenkel, E. (2008). Nanoparticles for drug delivery in cancer treatment. Urologic Oncology Seminars and Original Investigations, 26(1), 57–64. https://doi.org/10.1016/j.urolonc.2007.03.015
- Heldin, C., Rubin, K., Pietras, K., & Östman, A. (2004). High interstitial fluid pressure — an obstacle in cancer therapy. Nature Reviews. Cancer, 4(10), 806–813. https://doi.org/10.1038/nrc1456
- Iyer, A. K., Khaled, G., Fang, J., & Maeda, H. (2006). Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discovery Today, 11(17–18), 812–818. https://doi.org/10.1016/j.drudis.2006.07.005
- Maeda, H., Bharate, G. Y., & Daruwalla, J. (2009). Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. European Journal of Pharmaceutics and Biopharmaceutics, 71(3), 409–419. https://doi.org/10.1016/j.ejpb.2008.11.010
- Maeda, H., Sawa, T., & Konno, T. (2001). Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. Journal of Controlled Release, 74(1–3), 47–61. https://doi.org/10.1016/s0168-3659(01)00309-1
- Malam, Y., Loizidou, M., & Seifalian, A. M. (2009). Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends in Pharmacological Sciences, 30(11), 592–599. https://doi.org/10.1016/j.tips.2009.08.004
-
Matsumura, Y., & Maeda, H. (1986). A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Research, 46(12), 6387–6392.
- Moghimi, S., & Patel, H. (1998). Serum-mediated recognition of liposomes by phagocytic cells of the reticuloendothelial system – The concept of tissue specificity. Advanced Drug Delivery Reviews, 32(1–2), 45–60. https://doi.org/10.1016/s0169-409x(97)00131-2
- Pirollo, K. F., & Chang, E. H. (2008). Does a targeting ligand influence nanoparticle tumor localization or uptake? Trends in Biotechnology, 26(10), 552–558. https://doi.org/10.1016/j.tibtech.2008.06.007
- Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006). Targeting multidrug resistance in cancer. Nature Reviews Drug Discovery, 5(3), 219–234. https://doi.org/10.1038/nrd1984
- Tenzer, S., Docter, D., Kuharev, J., Musyanovych, A., Fetz, V., Hecht, R., Schlenk, F., Fischer, D., Kiouptsi, K., Reinhardt, C., Landfester, K., Schild, H., Maskos, M., Knauer, S. K., & Stauber, R. H. (2013). Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nature Nanotechnology, 8(10), 772–781. https://doi.org/10.1038/nnano.2013.181
- Unezaki, S., Maruyama, K., Hosoda, J., Nagae, I., Koyanagi, Y., Nakata, M., Ishida, O., Iwatsuru, M., & Tsuchiya, S. (1996). Direct measurement of extravasation of polyethyleneglycol-coated liposomes into solid tumor tissue by in vivo fluorescence. International Journal of Pharmaceutics, 144(1), 11–17.
- Zhang, D., Wu, M., Zeng, Y., Liao, N., Cai, Z., Liu, G., Liu, X., & Liu, J. (2016). Lipid micelles packaged with semiconducting polymer dots as simultaneous MRI/photoacoustic imaging and photodynamic/photothermal dual-modal therapeutic agents for liver cancer. Journal of Materials Chemistry B, 4(4), 589–599. https://doi.org/10.1039/c5tb01827g
Cite this article
-
APA : Zahid, D., Tahir, R., & Ashfaq, W. (2024). Nanocarrier-Based Therapeutics and Theranostics Drug Delivery Systems for Next Generation of Liver Cancer Nanodrug Modalities. Global Pharmaceutical Sciences Review, IX(II), 18-29. https://doi.org/10.31703/gpsr.2024(IX-II).03
-
CHICAGO : Zahid, Dua, Rabia Tahir, and Wajiha Ashfaq. 2024. "Nanocarrier-Based Therapeutics and Theranostics Drug Delivery Systems for Next Generation of Liver Cancer Nanodrug Modalities." Global Pharmaceutical Sciences Review, IX (II): 18-29 doi: 10.31703/gpsr.2024(IX-II).03
-
HARVARD : ZAHID, D., TAHIR, R. & ASHFAQ, W. 2024. Nanocarrier-Based Therapeutics and Theranostics Drug Delivery Systems for Next Generation of Liver Cancer Nanodrug Modalities. Global Pharmaceutical Sciences Review, IX, 18-29.
-
MHRA : Zahid, Dua, Rabia Tahir, and Wajiha Ashfaq. 2024. "Nanocarrier-Based Therapeutics and Theranostics Drug Delivery Systems for Next Generation of Liver Cancer Nanodrug Modalities." Global Pharmaceutical Sciences Review, IX: 18-29
-
MLA : Zahid, Dua, Rabia Tahir, and Wajiha Ashfaq. "Nanocarrier-Based Therapeutics and Theranostics Drug Delivery Systems for Next Generation of Liver Cancer Nanodrug Modalities." Global Pharmaceutical Sciences Review, IX.II (2024): 18-29 Print.
-
OXFORD : Zahid, Dua, Tahir, Rabia, and Ashfaq, Wajiha (2024), "Nanocarrier-Based Therapeutics and Theranostics Drug Delivery Systems for Next Generation of Liver Cancer Nanodrug Modalities", Global Pharmaceutical Sciences Review, IX (II), 18-29
-
TURABIAN : Zahid, Dua, Rabia Tahir, and Wajiha Ashfaq. "Nanocarrier-Based Therapeutics and Theranostics Drug Delivery Systems for Next Generation of Liver Cancer Nanodrug Modalities." Global Pharmaceutical Sciences Review IX, no. II (2024): 18-29. https://doi.org/10.31703/gpsr.2024(IX-II).03